-The Times of India India's space agency Isro bent rules for private firm Devas to sign a deal for multimedia services, projecting a paltry Rs 1,120 crore revenue over a 12-year period that would not even have covered the cost of launching two satellites for the promised service, the Comptroller and Auditor General (CAG) has said.  In a report submitted to Parliament on Tuesday, the official auditor gave the Prime Minister's Office...

Justice Markandey Katju's prescription for a regulated media regime is a misplaced step that can actually de-democratise the fourth estate. IT is open season on the political class and the news media. But then, again, it's more like a chase of one's own tail. A self-righteous, delusional, Anna-Baba NGO-ised fringe sets out to stigmatise politics and Members of Parliament; the news media salivate at the prospect and rush to provide...

A universal pension scheme for social protection must be part of a broader strategy of economic expansion different from the present neoliberal order. INDIA must be one of the worst countries in the world in terms of not providing even minimal social security for most of its people. This is not just a major failure of the development project in the country – it is also a significant cause of...

Inflation in India rose above expectations in April, making life difficult for the nation's central bank as it tries to revive an economy facing increased stagflation risks. The Reserve Bank of India last month cut its policy rate for the first time in three years to boost sagging growth. But inflation has remained stubbornly high, raising concerns the economy may be facing a nightmare scenario of slowing growth and rising prices. On...

Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs' claims of cheap access and affordability for patented drugs. Such protests, which began first in Europe, and have now spread to the US, could make it more difficult for pharma MNCs in developing countries to convince sceptical governments...